Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.

Manuel Puig-Domingo,Alfonso Soto,Eva Venegas, Ricardo Vilchez,Concepción Blanco,Fernando Cordido,Tomás Lucas,Mónica Marazuela,Rosa Casany,Guillem Cuatrecasas,Carmen Fajardo,María Ángeles Gálvez,Silvia Maraver,Tomás Martín,Enrique Romero,Miguel Paja,Antonio Picó,Ignacio Bernabeu,Eugenia Resmini

Endocrinología y Nutrición (English Edition)（2016）

引用 18|浏览15

暂无评分

摘要

In clinical practice lanreotide treatment combinations are useful options for patients with acromegaly when monotherapy is insufficient; particularly, the combination of lanreotide and pegvisomant in patients not controlled with either SSA or pegvisomant alone has high efficacy and is well-tolerated.

查看译文

关键词

Acromegaly,Lanreotide,Cabergoline,Pegvisomant,IGF-I,Somatostatin analogues

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要